All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
DELPHINUS: Daratumumab plus chemotherapy in pediatric patients with R/R ALL or LL
|
The phase II DELPHINUS trial (NCT03384654) assessed the safety and efficacy of daratumumab, an anti-CD38 monoclonal antibody, plus backbone chemotherapy in pediatric patients with B-cell ALL after ≥2 relapses (n = 7), and in pediatric and young adult patients with T-cell ALL (pediatric, n = 24; young adult, n = 5) and LL (n = 10) in first relapse.1 Results from this trial were published in Blood by Bhatla et al.1 |
| Key learnings: |
|
CR rates after Cycle 2 in the pediatric T-cell ALL, young adult T-cell ALL, and T-cell LL cohorts were 50%, 60.0%, and 40%, respectively, with overall response rates of 83.3%, 80.0%, and 50.0%. No patients in the B-cell ALL cohort achieved a CR and the cohort was closed due to futility. |
|
In the pediatric T-cell ALL, young adult T-cell ALL, and T-cell LL cohorts, the observed 24-month EFS rates were 36.1%, 20.0%, and 20.0%, the observed 24-month OS rates were 41.3%, 25.0%, and 20.0%, and allo-HSCT rates were 75.0%, 60.0%, and 30.0%, respectively. |
|
The combination treatment was well tolerated, with no new safety concerns observed, aligning with known daratumumab safety profiles in adult patients with R/R multiple myeloma. |
|
Daratumumab combined with chemotherapy demonstrates potential in pediatric and young adult patients with R/R T-cell ALL and LL, showing encouraging response rates and serving as a bridge to allo-HSCT. Although daratumumab did not show efficacy in patients with B-cell ALL, the results support its role in R/R T-cell ALL/LL. |
Abbreviations: ALL, acute lymphoblastic leukemia; allo-HSCT, allogeneic hematopoietic stem cell transplant; CR, complete response; EFS, event-free survival; LL, lymphoblastic lymphoma; OS, overall survival; R/R, relapsed/refractory.
- Bhatla T, Hogan L, Teachey DT, et al. Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: DELPHINUS study. Blood. 2024. Online ahead of print. DOI: 1182/blood.2024024493
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
12 votes - 29 days left ...
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox